Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (+)-Tranylcypromine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 11/20 | 1.00 |
| ▸ | MAOA known ✓ | P21397 | 7/20 | 1.00 |
| ▸ | KDM1A | O60341 | 14/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CYP2A6 | P11509 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (+)-Tranylcypromine SCHEMBL145650 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL29360959 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL13764364 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL13785162 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL34339 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL1649712 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL4740285 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL40651 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL1720497 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL2755938 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2906208-A1 | THERAPEUTIC TREATMENT | Sears, Douglas (US) | 2015-08-19 | — | — | EP | disclosed |
| EP-2254564-A1 | COMBINATIONS COMPRISING 3-PHENYLSULFONYL-8-PIPERAZINYL-1YL-QUINOLINE | Glaxo Group Limited (GB) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009074607-A1 | COMBINATIONS COMPRISING 3-PHENYLSULFONYL-8-PIPERAZINYL-1YL-QUINOLINE | GLAXO GROUP LIMITED (GB) | 2009-06-18 | — | — | WO | disclosed |
| CN-1960781-A | Therapeutic combination for treatment of alzheimers disease | WARNER LAMBERT CO (US) | 2007-05-09 | — | — | CN | disclosed |
| EP-1737539-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | Warner-Lambert Company LLC (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005099823-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | WARNER-LAMBERT COMPANY LLC (US) | 2005-10-27 | — | — | WO | disclosed |
| US-6060642-A | TRANSGENIC MICE MODELS FOR GENE FUNCTION, WHEREIN THE TRANSGENIC MICE ARE CHARACTERIZED BY HAVING ALTERED SEROTONIN 5-HT6 RECEPTOR GENE FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-05-09 | — | — | US | disclosed |